ReleaseWire Connect

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQBVenture Market:INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced today that it will seek regulatory guidance from the United Kingdom's MHRA as a Reference Member State in Europe before submitting its European application for its FlutiCare™ (50mcg fluticasone propionate) 60 and 120 sprays/bottle.

Innovus Pharmaceuticals Inc. (OTCQB:INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative, and effective over-the-counter medicine and consumer care products, plans to launch a new product into a multibillion dollar market in the near-term. After acquiring over-the-counter rights to FlutiCare™ - a leading prescription nasal steroid – in February 2015, the company expects to receive regulatory approval later this year.

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced today that it signed a manufacturing agreement for the supply of its FlutiCare™ 60 and 120 spray/bottles. Innovus signed the agreement in anticipation of the FDA's decision, expected between July-September of this year, on the ANDA application for the drug.

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCMKTS:INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases today announced today that it has entered into an exclusive license and distribution agreement with BroadMedSAL, a Lebanese company ("BroadMed") under which Innovus Pharma granted to BroadMed an exclusive license to market and sell Innovus product EjectDelay® indicated for treatment of premature ejaculation in Lebanon. Under the agreement, Innovus Pharma is eligible to receive up to $6.2 million dollars in upfront and sales milestone payments plus transfer price.

Innovus Pharmaceuticals Inc. (OTCQB:INNV), a provider of over-the-counter and consumer products for men and women's health, vitality, and respiratory diseases, recently acquired Beyond Human for a cash purchase price of $630,000. The acquisition provided the company with natural testosterone booster supplements, including Beyond T Human® and Human Growth Agent HGA® that generated $2.2 million in revenue and $400,000 in profit last year.

An uplisting to a national exchange is an important goal for many small over-the-counter companies in order to gain credibility and reach a wider base of potential investors. By holding companies to a higher standard, an uplisting creates a higher level of visibility, exposure, and legitimacy for companies that are able to meet the stringent prerequisites.

Innovus Pharmaceutical, Inc. (OTCQB:INNV) and Lipocine Inc. are two specialty pharmaceutical companies focused on men and women's health that have PDUFA and ANDA dates scheduled over the next few months that could significantly alter their future prospects.

Telecorp, Inc. (OTCMarkets:TLNUF) ("Telecorp" or the "Company"), a growing provider of software communications solutions, announced today that the election of Mr. Jason Cataldo as its President & Chief Executive Offer and Chairman of the Board of Directors. Mr. Cataldo succeeds Mr. Paul Phillips in the President & Chief Executive Officer and Chairman role to move the company into E-commerce and strong revenue generation.

Golden Age Resources Inc. (OTCPINK:GDAR), a leading acquisition and development company, announced today that it entered the highly profitable pharmaceutical business with the signing of a term sheet with Biopharma Pravo alpha for the perpetual exclusive worldwide rights for six products for a potential of 20 billion dollar markets. Under the terms of the signed term sheet, GDAR will have an exclusive perpetual pre-paid worldwide rights for the following products focusing on cardiovascular, anti-microbial, immunity and pain relief.